TY - JOUR
T1 - Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation
T2 - A Nationwide Cohort Study
AU - Nielsen, Peter Brønnum
AU - Melgaard, Line
AU - Overvad, Thure Filskov
AU - Jensen, Martin
AU - Larsen, Torben Bjerregaard
AU - Lip, Gregory Y H
AU - PRESTIGE-AF Consortium
PY - 2022/8
Y1 - 2022/8
N2 - BACKGROUND: In patients with intracerebral hemorrhage (ICH) and prevalent atrial fibrillation (AF), the optimal stroke prevention strategy is unclear. We sought to estimate the risk of cerebrovascular events among ICH survivors with AF.METHODS: We used the Danish Stroke Registry to identify patients with incident ICH and prevalent AF between 2003 and 2018. Key inclusion/exclusion criteria of the PRESTIGE-AF (Prevention of Stroke in Intracerebral hemorrhage Survivors With Atrial Fibrillation) trial were applied. Cumulative incidence of recurrent ICH, cerebrovascular ischemic event, and all-cause death were investigated after one year.RESULTS: A total of 1885 patients (median age 80.0 years; 47.6% females) were included in the study. We observed 191 cerebrovascular events and 650 all-cause deaths, and more cerebrovascular ischemic events (N=63) than recurrent ICH events (N=40). Risks of recurrent ICH, cerebrovascular ischemic event, and all-cause death were 1.5%, 3.2%, and 30.3%, respectively, among patients not exposed to OAC during follow-up. The cumulative incidences were 2.8% for recurrent ICH, 3.2% for cerebrovascular ischemic events, and 22.0% for all-cause death among patients initiating/resuming OAC during follow-up.CONCLUSIONS: We observed a high risk of cerebrovascular ischemic events and a very high risk of all-cause death at one year after the incident ICH. The results of ongoing clinical trials are warranted to determine optimal stroke prevention treatment among ICH survivors with concomitant AF.
AB - BACKGROUND: In patients with intracerebral hemorrhage (ICH) and prevalent atrial fibrillation (AF), the optimal stroke prevention strategy is unclear. We sought to estimate the risk of cerebrovascular events among ICH survivors with AF.METHODS: We used the Danish Stroke Registry to identify patients with incident ICH and prevalent AF between 2003 and 2018. Key inclusion/exclusion criteria of the PRESTIGE-AF (Prevention of Stroke in Intracerebral hemorrhage Survivors With Atrial Fibrillation) trial were applied. Cumulative incidence of recurrent ICH, cerebrovascular ischemic event, and all-cause death were investigated after one year.RESULTS: A total of 1885 patients (median age 80.0 years; 47.6% females) were included in the study. We observed 191 cerebrovascular events and 650 all-cause deaths, and more cerebrovascular ischemic events (N=63) than recurrent ICH events (N=40). Risks of recurrent ICH, cerebrovascular ischemic event, and all-cause death were 1.5%, 3.2%, and 30.3%, respectively, among patients not exposed to OAC during follow-up. The cumulative incidences were 2.8% for recurrent ICH, 3.2% for cerebrovascular ischemic events, and 22.0% for all-cause death among patients initiating/resuming OAC during follow-up.CONCLUSIONS: We observed a high risk of cerebrovascular ischemic events and a very high risk of all-cause death at one year after the incident ICH. The results of ongoing clinical trials are warranted to determine optimal stroke prevention treatment among ICH survivors with concomitant AF.
KW - anticoagulants
KW - atrial fibrillation
KW - epidemiology
KW - hemorrhagic stroke
KW - ischemic stroke
KW - Humans
KW - Risk Factors
KW - Survivors
KW - Male
KW - Stroke/etiology
KW - Anticoagulants/therapeutic use
KW - Cerebral Hemorrhage/complications
KW - Aged, 80 and over
KW - Female
KW - Aged
KW - Atrial Fibrillation/complications
KW - Cohort Studies
UR - http://www.scopus.com/inward/record.url?scp=85133307904&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.121.038331
DO - 10.1161/STROKEAHA.121.038331
M3 - Journal article
C2 - 35414198
SN - 0039-2499
VL - 53
SP - 2559
EP - 2568
JO - Stroke
JF - Stroke
IS - 8
M1 - 101161STROKEAHA121038331
ER -